Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsMRKMerck & Co., Inc.$122.55+0.1%$115.92$75.40▼$125.14$302.67B0.188.53 million shs14.75 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+811.78%MRKMerck & Co., Inc.0.00%+10.05%+9.58%-0.87%+57.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsMRKMerck & Co., Inc.$122.55+0.1%$115.92$75.40▼$125.14$302.67B0.188.53 million shs14.75 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+811.78%MRKMerck & Co., Inc.0.00%+10.05%+9.58%-0.87%+57.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 2.36Hold$169.88-23.27% DownsideMRKMerck & Co., Inc. 2.68Moderate Buy$128.184.59% UpsideCurrent Analyst Ratings BreakdownLatest MRK and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/13/2026MRKMerck & Co., Inc. UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $145.004/6/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$125.00 ➝ $135.003/30/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.003/20/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$120.00 ➝ $125.003/17/2026MRKMerck & Co., Inc. Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/12/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$135.00 ➝ $150.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara TherapeuticsN/AN/AN/AN/A$14.92 per shareN/AMRKMerck & Co., Inc.$65.01B4.66$11.43 per share10.72$18.60 per share6.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/AMRKMerck & Co., Inc.$18.25B$3.5534.5212.532.7613.59%27.55%10.73%8/4/2026 (Estimated)Latest MRK and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.77%+5.75%95.77%14 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A4.624.62MRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%MRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9031.44 million30.22 millionNo DataMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableMRK and CDTX HeadlinesRecent News About These CompaniesGILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy4 hours ago | finance.yahoo.comMRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer4 hours ago | zacks.comLegal & General Group Plc Has $2.08 Billion Stock Position in Merck & Co., Inc. $MRKMay 25 at 6:34 AM | marketbeat.comRHL Group LLC Makes New Investment in Merck & Co., Inc. $MRKMay 25 at 6:26 AM | marketbeat.comMorningstar Investment Management LLC Sells 93,011 Shares of Merck & Co., Inc. $MRKMay 25 at 6:26 AM | marketbeat.comMerck & Co., Inc. $MRK Holdings Decreased by New Age Alpha Advisors LLCMay 25 at 6:09 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Bought by Fisher Asset Management LLCMay 25 at 4:34 AM | marketbeat.comChoate Investment Advisors Buys 13,581 Shares of Merck & Co., Inc. $MRKMay 25 at 4:33 AM | marketbeat.comGenus Capital Management Inc. Takes Position in Merck & Co., Inc. $MRKMay 25 at 4:02 AM | marketbeat.comSickly Healthcare Stocks Are Perking Up. For Contrarian Investors, Buying Now Could Be Just the Remedy to Protect Your Portfolio.May 24 at 5:07 PM | barchart.comMondrian Investment Partners LTD Sells 38,085 Shares of Merck & Co., Inc. $MRKMay 24 at 6:26 AM | marketbeat.comSmead Capital Management Inc. Sells 196,374 Shares of Merck & Co., Inc. $MRKMay 24 at 6:18 AM | marketbeat.comCatalyst Funds Management Pty Ltd Buys 22,100 Shares of Merck & Co., Inc. $MRKMay 24 at 4:08 AM | marketbeat.comMerck Oncology Updates Spark Interest In Sacituzumab Tirumotecan And ValuationMay 23 at 8:58 PM | finance.yahoo.comMerck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary EndpointsMay 23 at 10:58 AM | finance.yahoo.comLegato Capital Management LLC Buys 8,759 Shares of Merck & Co., Inc. $MRKMay 23 at 6:53 AM | marketbeat.comLSV Asset Management Cuts Stake in Merck & Co., Inc. $MRKMay 23 at 6:39 AM | marketbeat.comMerck Completes $6 Billion Multi-Tranche Senior Notes OfferingMay 22 at 5:51 PM | tipranks.comUS Equity Indexes Rise, Crude Oil Off Session Highs as Iran Peace Talks Press AheadMay 22 at 5:27 PM | finance.yahoo.comStock Market Today: S&P 500, Nasdaq Score Weekly Wins As Dow Logs Record HighMay 22 at 5:27 PM | finance.yahoo.comHealthcare Stocks Are on Fire -- Don't Miss These OpportunitiesMay 22 at 5:27 PM | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and CDTX Company DescriptionsCidara Therapeutics NASDAQ:CDTXCidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Merck & Co., Inc. NYSE:MRK$122.55 +0.14 (+0.11%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$122.52 -0.02 (-0.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
